全文获取类型
收费全文 | 1516篇 |
免费 | 155篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 69篇 |
妇产科学 | 21篇 |
基础医学 | 166篇 |
口腔科学 | 38篇 |
临床医学 | 204篇 |
内科学 | 313篇 |
皮肤病学 | 17篇 |
神经病学 | 69篇 |
特种医学 | 258篇 |
外科学 | 210篇 |
综合类 | 35篇 |
预防医学 | 79篇 |
眼科学 | 12篇 |
药学 | 98篇 |
中国医学 | 5篇 |
肿瘤学 | 80篇 |
出版年
2023年 | 9篇 |
2021年 | 21篇 |
2020年 | 15篇 |
2019年 | 16篇 |
2018年 | 32篇 |
2017年 | 18篇 |
2016年 | 30篇 |
2015年 | 30篇 |
2014年 | 41篇 |
2013年 | 41篇 |
2012年 | 38篇 |
2011年 | 42篇 |
2010年 | 43篇 |
2009年 | 73篇 |
2008年 | 54篇 |
2007年 | 29篇 |
2006年 | 37篇 |
2005年 | 23篇 |
2004年 | 37篇 |
2003年 | 42篇 |
2002年 | 34篇 |
2001年 | 30篇 |
2000年 | 39篇 |
1999年 | 29篇 |
1998年 | 57篇 |
1997年 | 55篇 |
1996年 | 66篇 |
1995年 | 51篇 |
1994年 | 52篇 |
1993年 | 57篇 |
1992年 | 32篇 |
1991年 | 17篇 |
1990年 | 26篇 |
1989年 | 36篇 |
1988年 | 49篇 |
1987年 | 43篇 |
1986年 | 44篇 |
1985年 | 30篇 |
1984年 | 23篇 |
1983年 | 20篇 |
1982年 | 30篇 |
1981年 | 21篇 |
1980年 | 18篇 |
1979年 | 16篇 |
1978年 | 13篇 |
1977年 | 20篇 |
1976年 | 19篇 |
1975年 | 18篇 |
1972年 | 6篇 |
1968年 | 11篇 |
排序方式: 共有1678条查询结果,搜索用时 140 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
6.
7.
Carter R Coberley Gary A Puckrein Angela C Dobbs Matthew A McGinnis Sadie S Coberley Dexter W Shurney 《Disease management》2007,10(3):147-155
In addition to race and ethnicity, specific geographic regions are associated with poorer outcomes of care. Individuals with diabetes experiencing health disparities typically have worse long-term outcomes, such as increased diabetes complications and mortality. Zip code mapping, or geocoding, was utilized in this study to identify regions of the United States with high diabetes prevalence rates and to identify areas with high densities of minority populations. Use of this methodology to examine the effect of disease management on a large, diverse diabetes population revealed greater improvement in clinical testing rates in health disparity zones compared with members living outside of these areas. In particular, significant improvement was achieved by members living in minority zip codes and by members aged 65 years or older. These findings demonstrate that members living in areas of health disparity obtain even greater benefit from diabetes disease management program participation, helping to reduce gaps in care. 相似文献
8.
9.
10.
Rupert C M Jones Shirley Copper Oksana Riley Frank Dobbs 《The British journal of general practice》2002,52(480):567-568
Pulmonary rehabilitation is an effective intervention for patients with chronic obstructive pulmonary disease (COPD). It is usually available only through selected hospitals. A pilot study was undertaken to see if pulmonary rehabilitation performed by the primary health care team in one practice was feasible. Fourteen patients were recruited; 13 completed the programme and one year of follow-up. The programme was well received by patients and staff. There were not enough suitable patients among a practice list of 10,500 to justify the running of this programme for a single practice; one primary care group would suffice 相似文献